Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.55 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003870 | 0.82 | ABCB1 (0.46) | P2RY1KCNH2ABCB1ABCC1KDR | |
| SCHEMBL3836164 | 0.78 | CYP17A1 (0.51) | CYP17A1P2RY1KCNH2ABCB1ALOX5AP | |
| SCHEMBL3830430 | 0.78 | F10 (0.52) | CYP17A1 | |
| SCHEMBL24196483 | 0.78 | CYP17A1 (0.58) | CYP17A1EGLN2ABCB1ABCC1SYK | |
| SCHEMBL2392457 | 0.77 | METAP1 (0.56) | CYP17A1METAP1 | |
| SCHEMBL8160635 | 0.76 | CYP17A1 (0.49) | CYP17A1EGLN2TRPV1KDR | |
| SCHEMBL31307614 | 0.76 | CYP17A1 (0.56) | CYP17A1METAP1EGLN2ABCB1KDR | |
| SCHEMBL14512376 | 0.75 | CYP17A1 (0.50) | CYP17A1ABCB1ABCC1KDR | |
| SCHEMBL7347458 | 0.75 | CYP17A1 (0.55) | CYP17A1EGLN2ABCB1KDR | |
| SCHEMBL2363945 | 0.75 | CYP17A1 (0.53) | CYP17A1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | CYP17A1 295/4885P2RY1 1269/4885KCNH2 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.